Peer reviewed
PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColiTis.
Frontiers in Pharmacology (2024). PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColiTis.
Frontiers in PharmacologyAccessed Aug 5, 2026
Registry record
Source metadata
- Publisher
- Frontiers in Pharmacology
- Source type
- Peer reviewed
- Registry ID
pubmed-kpv-fk506-colitis-2024- DOI
- 10.3389/fphar.2024.1442876
- PMID
- 39211778
Source usage
Not yet linked from a public content page
This record may be retained for an upcoming review or for internal source normalization.
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.